Most viewed in the last 7 days from JAMA Cardiology:
Does plozasiran, an investigational APOC3-targeted small interfering–RNA therapeutic, safely and effectively reduce serum triglyceride level in patients with severe hypertriglyceridemia?
ja.ma/3JpT3o6
A true pleasure to interview a lipid expert like Dr. Gaudet and learn more about revolutionary therapies in lipid-lowering. Many thanks to FITsOnTheGo American College of Cardiology. Definitely also check out the full paper: jamanetwork.com/journals/jamac… JAMA Cardiology
BiotechObserver Bellinger pointed to #inclisiran + #PCSK9 MAbs + pointed to background genetic diversity.
Remember, these are complex pathways where 1 sort of particle is converted to another. E.g. ApoC3 kd increases LDLc in patients with v high, but not low starting TRLs. $ARWR $IONS $VERV